Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Imunoterapia ou terapia direcionada com ou sem radiocirurgia estereotáxica para pacientes com metástases cerebrais de melanoma ou câncer de pulmão de células não pequenas (USZ-STRIKE)

9 de novembro de 2026 atualizado por: ETOP IBCSG Partners Foundation

Um estudo multicêntrico randomizado de fase III de radiocirurgia estereotáxica, além da terapia sistêmica padrão para pacientes com melanoma metastático ou NSCLC metastático recém-diagnosticado e metástases cerebrais assintomáticas ou oligossintomáticas

The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

180

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Most important inclusion criteria:

  • Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.

  • Requirements for brain metastases:

  • Brain metastases must be previously untreated, except for surgery.

  • Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.

  • Number and size of metastases at diagnosis of brain metastases:

    • Maximum 1-10 brain metastases at screening
    • At least one brain metastasis must be of ≥5 mm in diameter
    • In case of 1-4 brain metastases:
    • Longest diameter of largest brain metastasis must be ≤30 mm
    • In case of 5-10 brain metastases:
    • Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
    • Maximum cumulative brain metastases volume must be ≤30 mL
  • Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC

  • Requirements for patients with melanoma:

  • Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).

  • BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).

  • Requirements for patients with NSCLC:

  • Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.

  • Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)

  • Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).

  • Age of 18 years or older

  • Karnofsky performance status of 60 or more

  • Life expectancy >12 weeks

  • Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).

  • Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.

  • Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.

Most important exclusion criteria:

  • Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
  • Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
  • Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
  • Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
  • Prior whole brain irradiation or focal radiation therapy to the brain
  • Prior systemic treatment for brain metastases
  • Contra-indication for SRS
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  • Women who are pregnant or in the period of lactation.
  • Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Standard systemic treatment with stereotactic radiosurgery (SRS)

Arm A

Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of >20 mm or for >4 brain metastases.

For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation.

Systemic therapy follows the current standard of care, according to the type of the primary tumour.

  • For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of

    • an approved immune-checkpoint inhibition combination therapy (cohort 1a) or
    • an approved immune-checkpoint inhibition monotherapy (cohort 1b).
  • For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).

  • For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy).

Outros nomes:
  • padrão de tratamento de cuidados
Comparador Ativo: Standard systemic treatment without stereotactic radiosurgery

Arm B

Systemic therapy follows the current standard of care, according to the type of the primary tumour.

  • For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of

    • an approved immune-checkpoint inhibition combination therapy (cohort 1a) or
    • an approved immune-checkpoint inhibition monotherapy (cohort 1b).
  • For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).

  • For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy).

Outros nomes:
  • padrão de tratamento de cuidados

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
CNS-specific PFS, locally assessed as per iRANO criteria
Prazo: from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months

The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy.

from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Cadeira de estudo: Michael Weller, MD, University of Zurich
  • Cadeira de estudo: Rolf Stahel, MD, ETOP IBCSG Partners Foundation

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de novembro de 2022

Conclusão Primária (Estimado)

1 de junho de 2027

Conclusão do estudo (Estimado)

1 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

23 de agosto de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de agosto de 2022

Primeira postagem (Real)

31 de agosto de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever